Available Studies



Study on a new oral contraceptive Calliop3

étude clinique anovulant

What is the objective of the CALLIOP3 study?

The CALLIOP3 study examines whether a study drug called LPRI-CF113 is an effective method of birth control for women aged 13-45.

What is the study drug and how does it work?

The study drug is a daily hormonal pill. It has been tested in adult women and showed no signs of harmful side effects. The study drug is currently considered experimental. This is because it has not been reviewed and approved by regulatory bodies such as the FDA.

The study drug is designed to prevent pregnancy by blocking the release of a woman's egg. This can help reduce or stop monthly bleeding. The study drug may also prevent side effects such as weight gain and bloating.

All study participants will receive study medication free of charge for a period of 12 months.

Who can participate in the study?

Your child/partner can participate in the CALLIOP3 study if she is sexually active and has had regular periods for at least 3 months.

See brochure for more details

To learn more about the study, contact us.


New study on the treatment of lichen sclerosus of the vulva

At the beginning of the year 2023, we will begin a new research project on the treatment of lichen sclerosus of the vulva with a new medication. If you suffer from this disease, you can register to be called when the project begins.


To learn more about the study, contact us.


Application to a clinical study

Thank you for helping us to advance medical research

Clinique de Recherche en Santé des Femmes

1200 avenue Germain-des-Prés, suite 100
Québec, Qc. G1V3M7

Phone : 418-650-2295
Fax : 418-650-1374